Myelodysplastic Syndromes, Acute Myeloid Leukemia
Conditions
Keywords
relapsed/refractory, R/R, Phase 1/2, Sabatolimab, Magrolimab, Azacitidine, Myelodysplastic Syndromes, MDS, Acute myeloid leukemia, AML, TIM-3, CD47
Brief summary
This study is to determine the safety and preliminary efficacy of sabatolimab in combination with magrolimab and azacitidine in adult participants with 1L unfit Acute Myeloid Leukemia (AML) or with 1L higher risk Myelodysplastic Syndromes (MDS), and sabatolimab in combination with magrolimab in participants with relapsed or refractory (R/R) AML.
Detailed description
The primary purpose of the Safety run-in is to rule out excessive toxicity and investigate safety of the combination of sabatolimab with azacitidine and magrolimab in previously untreated participants with higher-risk MDS and unfit AML. The primary purpose of the combined Safety Run-in and Expansion is to assess the preliminary efficacy of the combination of sabatolimab with magrolimab with (cohort 1 and 2) or without (cohort 3) azacitidine in terms of achieving complete remission in 3 different indications: * Previously untreated participants with AML, who are unfit for intensive chemotherapy (1L unfit AML - cohort 1), * Previously untreated participants with higher-risk MDS (1L higher risk MDS - cohort 2), * Participants with R/R AML after having been previously treated with only first line venetoclax in combination with hypomethylating agent (VEN+HMA) (R/R AML - cohort 3).
Interventions
DRUGSabatolimab
Solution for intravenous infusion
DRUGMagrolimab
Solution for intravenous infusion
DRUGAzacitidine
Solution for subcutaneous injection or intravenous infusion
Sponsors
Novartis Pharmaceuticals
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Safety run in (1L higher risk MDS + 1L unfit AML) followed by parallel expansion cohorts (1L higher risk MDS, 1L unfit AML, relapsed/refractory AML)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Signed informed consent must be obtained prior to participation in the study. 2. Age ≥ 18 years at the date of signing the informed consent form (ICF) 3. Newly diagnosed with AML based on 2016 WHO classification (Arber et al 2016) and not suitable for intensive chemotherapy defined as: age ≥75, ECOG performance Status 2 or 3, or any of the following comorbidities: severe cardiac comorbidity (including congestive heart failure, LVEF ≤ 50%, chronic stable Angina) , pulmonary comorbidity (DLCO ≤ 65% or FEVI ≤ 65%). moderate hepatic impairment (with total Bilirubin \>1.5 to 3x ULN) , renal impairment (eGFR≥ 30 ml/min/1.73m\^2 to 45 30 ml/min/1.73m\^2), or other comorbidity incompatible with intensive chemotherapy per Investigator assessment and approved by the Novartis Medical monitor) OR Morphologically confirmed diagnosis of myelodysplastic syndrome (MDS) based on 2016 WHO classification (Arber et al 2016), that is intermediate, high or very high risk (higher risk) based on the revised International Prognostic Scoring System (IPSS-R) (Greenberg et al 2012), previously untreated for higher risk MDS \[1L higher risk MDS\]: * Intermediate (\>3-4.5 points) * High (\> 4.5-6 points) * Very high (\> 6 points) OR (for expansion only) Participants with AML relapsed or refractory to venetoclax in combination with a hypomethylating agent (VEN+HMA) as defined by failure to achieve bone marrow blast \<5% after at least 2 cycles of VEN+HMA (refractory) or relapsed after having achieved BM blast \<5% following previous treatment with VEN+HMA as first and the only line of treatment for AML 4. Eastern Cooperative Oncology Group (ECOG) performance status must be 0-2 for participants ≥ 75 years of age, OR 0-3 for participants \< 75 years of age 5. White blood cell (WBC) count ≤ 20 x 10\^3/μL prior to first dose of study treatment (may be reduced with leukapheresis, hydroxyurea, or oral etoposide) 6. Hemoglobin ≥ 9 g/dL prior to initial dose of study treatment. Transfusions are allowed to meet hemoglobin eligibility prior to first dose of study treatment
Exclusion criteria
1. Prior treatment with CD47 or signal regulatory protein alpha (SIRPα) targeting agents 2. Prior exposure to TIM-3 directed therapy 3. Prior therapy with immune checkpoint inhibitors (eg, anti-CTLA4, anti-PD-1, anti-PDL1, or anti-PD-L2) or cancer vaccines is not allowed if the last dose of the drug was administered within 4 months prior to start of the study treatment 4. For participants with higher risk MDS only: Previous first-line treatment for intermediate, high, very high risk (higher risk) MDS (based on IPSS-R) with any antineoplastic agents including for example chemotherapy and hypomethylating agents such as decitabine or azacitidine. For participants with newly diagnosed AML only: Previous treatment at any time, with any approved or investigational antineoplastic agents for AML or higher risk MDS. Prior and concurrent therapy with hydroxyurea or oral etoposide (to reduce WBC count), supportive care ruxolitinib, erythroid and/or myeloid growth factors are allowed. 5. Acute promyelocytic leukemia 6. Known inherited or acquired bleeding disorders 7. Patients with CNS leukemia or neurologic signs and symptoms suggestive of CNS leukemia (unless CNS leukemia had been excluded) Other protocol defined inclusion/
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of participants with dose limiting toxicities (only for participants enrolled in the safety run-in part) | Cycle 1 Day 1 to the end of Cycle 2 (up to 14 days from the planned cycle 3 Day 1) ; Cycle = 28 Days | Assessment of tolerability of sabatolimab and magrolimab given together with azacitidine |
| Percentage of participants achieving complete remission (CR) according to Investigator assessment per treatment arm | Up to 4 years from last patient first treatment | Assessing the Complete Remission (CR) Rate in each treatment arm (including participants from safety run-in and expansion) per IWG -Cheson 2003 and ELN AML recommendations - Doehner 2017 (AML) and per modified IWG-MDS criteria- Cheson 2006 (MDS) in each treatment arm. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Peak of Serum Concentration (Cmax) sabatolimab and magrolimab | Day 1 of week 2, 5, 13 for sabatolimab. Day 1 or week 1, 5, 13 for magrolimab | Maximal serum concentration of sabatolimab and magrolimab |
| Trough serum concentration (Cmin) sabatolimab | Day 1 of week 2, 5, 9, 13, 25, 37, 49, 73, 97, end of treatment (EOT) (within 7 days after the last dose of study treatment), 30 days after last dose of sabatolimab, and 90 days after the last dose of sabatolimab for sabatolimab | Concentration of sabatolimab prior to next dosing or after end of treatment |
| Trough serum concentration (Cmin) magrolimab | Day 1 or week 1, 2, 5, 9, 13, 25, 37, 49, 73, 97, end of treatment (EOT) (within 7 days after the last dose of study treatment), 30 days after last dose of magrolimab for magrolimab | Concentration of magrolimab prior to next dosing or after end of treatment |
| Time from first occurrence of CR (complete remission) to relapse from CR or death due to any cause whichever occurs first (All 3 arms) | Up to 4 years from last patient first treatment | Assessing the duration of complete response defined as time from first occurence of CR per IWG -Cheson 2003) and ELN Doehner 2017 AML recommendations (AML) and per modified IWG-MDS criteria (MDS) to relapse from CR per IWG CHeson 2003 and ELN -Doehner 2017 AML recommendations (AML) and per modified IWG-MDS criteria Cheson 2006 (MDS) or death due to any cause ,whichever occurs first |
| Percentage of participants achieving CR, CR with incomplete hematologic recovery (CRi), or partial response (PR) as per Investigator (1L unfit AML and R/R AML arms only) | Up to 4 years from last patient first treatment | Assessing the overall response rate defined as proportion of participants achieving CR, CR with incomplete hematologic recovery (CRi), or partial response (PR) as per investigator assessment as per ELN -Doehner 2017 and IWG criteria -Cheson 2003 |
| Percentage of participants achieving CR or CRi (1L unfit AML and R/R AML arms only) | Up to 4 years from last patient first treatment | Assessing the \[CR + CRi\] rate defined as proportion of patients achieving complete remission or complete remission with incomplete hematologic recovery per IWG - Cheson 2003 and ELN AML recommendations -Doehner 2017 (AML) |
| Anti-drug-antibody prevalence at baseline | prior to first dose of sabatolimab on week 2 Day 1 and first dose of magrolimab on week 1 day 1 | Measuring immunogenicity to sabatolimab and magrolimab prior to exposure |
| Percentage of participants achieving CR with Measurable Residual Disease (MRD)-negative status(1L unfit AML and R/R AML arms only) | Up to Day 1 of cycle 13 ; Cycle=28 days | Assessing the rate of MRD-negative CR participants defined as proportion of participants in complete remission with no detectable minimal residual disease |
| Percentage of participants achieving CR or CRi with MRD-negative status (1L unfit AML and R/R AML arms only) | Up to Day 1 of Cycle 13 ; Cycle =28 days | Rate of MRD-negative participants Assessing the rate of MRD-negative CR /CRi participants defined as proportion of participants in either complete remission or complete remission with incomplete hematologic recovery with no detectable minimal residual disease |
| Percentage of participants achieving CR, marrow CR (mCR), partial response (PR), hematologic improvement (HI) per Investigator assessment (1L higher risk MDS arm only) | Up to 4 years from last patient first treatment | Assessing the overall response rate defined as proportion of patients achieving CR, marrow CR (mCR), partial response (PR), hematologic improvement (HI) per Investigator assessment according to modified IWG-MDS response criteria- Cheson 2006 |
| Percentage of participants who are red blood cells (RBC)/platelets transfusion independent (1L MDS arm only) | From start of treatment up to until 4 years after last patient first treatment | Assessing the improvement in RBC/platelets transfusion independence |
| Duration of transfusion independence (1L MDS arm only) | From start of treatment up to until 4 years after last patient first treatment | Assessing the time to RBC/platelets transfusion independence |
| Percentage of participants achieving CR or CRh (1L unfit AML and R/R AML arms only) | Up to 4 years from last patient first treatment | Assessing the \[CR + CR with partial hematologic recovery (CRh)\] rate defined as proportion of patients achieving complete remission or complete remission with partial hematological recovery per IWG and ELN AML recommendations (AML) |
| Anti-drug-antibody prevalence on treatment | Throughout study until 90 day safety follow up for sabatolimab and 30 day safety follow up for magrolimab | Measuring immunogenicity to sabatolimab and magrolimab on treatment and after treatment |
Outcome results
None listed